Current Management of Atherosclerotic Renovascular Disease – What Have We Learned from ASTRAL?

Constantina Chrysochou    Philip A. Kalra
Renal Department, Salford Royal Hospital, Salford, UK

Background

Although atheromatous renovascular disease (ARVD) is often a clinically silent disease, it may pose a considerable challenge for those involved in its investigation and management. It is usually part of a systemic syndrome that involves a complex interplay between intrinsic renal damage, concomitant cardiovascular disease and hypertension, so that patients are at high risk of and are prone to further renal and cardiovascular decline. Percutaneous interventional procedures that correct renal artery stenosis (RAS) lesions have been widely available for over 2 decades and whilst there is consensus regarding their benefit in specific clinical scenarios, there is less clarity regarding their applicability in the management of the majority of patients with ARVD, many of whom may have RAS as a co-incidental diagnosis.

Epidemiology

As many cases of ARVD are clinically unnoticed, its true epidemiology may be difficult to estimate. The incidence of ARVD in a large study of Medicare patients aged >65 years was 3.7 cases per 1,000 patient-years [1]. Disease prevalence is likely to be higher, and a survey that used Doppler ultrasound in an unselected sample of community-based elderly people revealed that almost 7% had...
anatomically significant RAS [2]. Diabetics and smokers are more at risk. ARVD is commonly associated with other vascular conditions, and so it is detected with a high frequency during investigation of other arterial beds; e.g. up to 30% of those with coronary artery disease [3], 30% with congestive cardiac failure and almost 60% with peripheral vascular disease [4] can be shown to have some degree of ARVD.

The detrimental link between the heart and kidneys in ARVD is well described, and the presence of ARVD in patients with coronary disease independently doubles the risk of mortality even when coronary revascularization is performed [5]. In turn, the frequent presence of other co-morbid cardiovascular diseases is reflected in the high incidence of premature cardiovascular events [6, 7] and death in patients with ARVD. Hence, only 5.1% of ARVD patients have normal cardiac structure and function [8], and they are almost 6 times more likely to die than to reach dialysis [1]. Survival rates are linked to baseline renal function and blood pressure control [7], amongst other factors, with >90% of patients being hypertensive. Whether ARVD is the cause of hypertension and CKD may often be difficult to elucidate, and it is likely that this atherogenic combination predates RAS development in many patients. Irrespective of whether a given RAS lesion is pathophysiologically important, supervening poorly controlled blood pressure in ARVD contributes to further renal decline and target organ damage. ARVD has been listed as the primary cause of end-stage renal disease (ESRD) in 5.8% of cases [9], and some investigators have found it to be responsible for at least 15% of ESRD in more elderly patients [10, 11]. However, we suspect that most of these latter cases represent incidental complications of the hypertension and long-standing CKD; support for this view is available in a study of a US dialysis population in which twice as many patients (11%) commenced dialysis with known ARVD than had this condition listed as the primary renal failure diagnosis [9].

**Renal Revascularization in ARVD**

Renal revascularization is performed in around 16% of newly diagnosed cases of ARVD in the United States [1], and endovascular procedures now account for over 95% of all these interventions. Angioplasty with stent insertion, or primary stenting, is preferred to angioplasty alone due to better arterial patency and markedly lower restenosis rates in atherosclerotic ostial RAS [12, 13], but the use of drug-eluting [14] devices has not been found to provide any additional advantage [15]. There is general consensus, but no evidence base, that renal revascularization should be performed in patients with anatomically significant RAS who present with particular clinical scenarios such as life-threatening, sudden onset or ‘flash’ pulmonary oedema [16], or oligo-anuric acute kidney injury (AKI) [17]. Other clinicians would feel that ARVD patients with multidrug-resistant renovascular hypertension and those with steadily deteriorating renal function should undergo revascularization procedures. However, there is little evidence to support the use of revascularization in these latter situations, which is also true for the vast majority of ARVD patients who present with asymptomatic CKD or hypertension and severe RAS. Some studies have shown that revascularization is efficacious in improving hypertension control in 50–85% of patients [18], but these experiences are not replicated in the literature, and results in terms of renal functional outcome have been even more variable. Most of these studies have been retrospective [19], observational or non-randomised, and results have been conflicting [20, 21]. Review of the many retrospective and prospective case series reported in the literature indicates that approximately 25% of patients show renal functional improvement, 25% deteriorate and 50% remain unchanged [12, 22] following revascularization. Distal athero-embolism may be partly responsible for some of the patients who deteriorate. In a prospective study of renal revascularization with distal embolic protection in a high-risk patient population, 60% of the filter baskets contained embolic material [15]. A minority of investigators have demonstrated that the use of distal protection embolic devices benefits renal functional outcome [23], but these findings have not been translated into a widespread change in practice by the renal stenting community.

Also, it should not be overlooked that even in skilled hands renal endovascular intervention is not risk-free, with about 3% of patients suffering a major vascular complication and over 10% having less serious (and usually reversible) adverse events such as contrast-related acute renal injury or major groin haematoma [24]. These risks may be increased in the elderly or those having many other co-morbidities. Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) have specific renoprotective effects, and guidelines endorse these drugs as first choice for the treatment of hypertension in renal disease [25], particularly with CKD and proteinuria >1 g/day. However, in patients with severe bilateral RAS, or severe stenosis of the artery supplying a single functioning kidney, ACE-I/ARB can re-
duce or eliminate glomerular filtration and may cause severe and progressive renal failure [26]. The risk is higher in bilateral RAS.

The ONTARGET study [27] has also raised questions regarding the clinical safety of combination therapy with ACE-I/ARB. In high-cardiovascular-risk patients aged >55 years, the hazards of the combination were found to be in excess of any benefits observed, when compared to therapy with sole agents.

**Rationale for a Large Randomised Controlled Trial**

To date, there have been 5 published randomised clinical trials (RCTs) comparing percutaneous renal revascularization and medical management in a mix of ARVD patients with hypertension and renal function varying from normal to moderate CKD (table 1) [28–32]. All 5 studies had small patient numbers (the largest study, the STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery trial, acronym ‘STAR’, enrolled 140 patients [32]) and only a short follow-up period. One of these RCTs primarily investigated the effectiveness of stenting over angioplasty in patients with ostial RAS, and has been alluded to already [31]. In the 3 other earlier studies [28–30], the revascularization technique did not involve stent insertion but angioplasty only; their major weaknesses were that none of them were powered adequately to address any of the main cardiovascular and renal functional outcomes relevant to patients with ARVD. A later meta-analysis of these 3 trials (n = 210) indicated that the mean improvement in blood pressure was slightly better in the angioplasty group; no significant differences in BP, sCr or drug dose between each group at 1 year; 22 patients in medical arm crossed over to angioplasty on clinical grounds.

**Table 1. RCTs comparing medical management to angioplasty ± stent insertion in ARVD**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Year of publication</th>
<th>Patients</th>
<th>Randomised treatment</th>
<th>Main endpoints</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Webster et al. [29]</td>
<td>1998</td>
<td>55</td>
<td>Angioplasty vs. medical treatment</td>
<td>Primary: BP and sCr at 6 months and the change in these from baseline; secondary: major events</td>
<td>Patients with bilateral RAS randomised to angioplasty experienced a statistically significant fall in BP; no clinical or biochemical difference in outcome noted in either group overall</td>
</tr>
<tr>
<td>Plouin et al. [30]</td>
<td>1998</td>
<td>49</td>
<td>Angioplasty (± stent insertion) vs. medical treatment</td>
<td>Primary: BP at termination and the change from baseline; secondary: treatment score and the incidence of complications</td>
<td>Mean BP did not differ between either group at 6 months; angioplasty resulted in more complications, but was more drug-sparing</td>
</tr>
<tr>
<td>van Jaarsveld et al. [28]</td>
<td>2000</td>
<td>106</td>
<td>Angioplasty vs. medical treatment</td>
<td>Primary: BP at 3 and 12 months; secondary: treatment score, sCr, sCr clearance, patency, incidence of complications</td>
<td>Mild drug-sparing effect noted at 3 months in angioplasty group; no significant differences in BP, sCr or drug dose between each group at 1 year; 22 patients in medical arm crossed over to angioplasty on clinical grounds</td>
</tr>
<tr>
<td>van de Ven et al. [31]</td>
<td>1999</td>
<td>84</td>
<td>Angioplasty vs. angioplasty + stent insertion</td>
<td>Primary: primary success rate of procedure, patency rate at 6 months; secondary: sCr and BP outcomes</td>
<td>Primary success rate was 57% (angioplasty alone) vs. 88% (angioplasty + stent), with better patency rate at 6 months (29 vs. 75%) and lower restenosis rates (48 vs. 14%) for the angioplasty + stent group; no difference in intention to treat for clinical results in either group</td>
</tr>
<tr>
<td>Bax et al. [32]</td>
<td>2009</td>
<td>140</td>
<td>Angioplasty + stent vs. medical treatment</td>
<td>Primary: reduction in eGFR &gt;20% compared to baseline; secondary: changes in BP, safety and cardiovascular morbidity and mortality</td>
<td>22% of patients in the medication group and 16% in the stent group reached the primary endpoint; no significant difference in terms of primary or secondary outcomes between either group; a number of stent-related complications occurred, including 2 stent-related deaths</td>
</tr>
</tbody>
</table>

BP = Blood pressure; sCr = Serum creatinine.
(predicted to occur in 50% of patients over 2 years in the medical therapy arm, falling to 20% of revascularized patients). In fact, only 22% of the patients in the medical therapy arm reached this endpoint, and only 46 of 64 patients allocated to revascularization actually underwent the procedure; not surprisingly, there was no difference in renal functional change or in any of the secondary endpoints (blood pressure control, cardiovascular safety events and mortality) between the 2 arms of the study. Furthermore, almost 10% of the patients who underwent revascularization either died or developed ESRD as a direct or indirect result of the procedure.

In order to fill this evidence gap in the management of atherosclerotic RAS the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial [34] was designed in the UK, and commenced patient recruitment in September 2000. The trial compared 2 equal-sized groups of patients with significant anatomical atherosclerotic RAS who were randomised to either endovascular revascularization with standard medical therapy (usually statin, anti-platelet and anti-hypertensive therapy), or to standard medical therapy alone. The primary endpoint was the rate of change of renal function over time, with secondary endpoints of blood pressure control, cardiovascular and renal events and mortality. After a recruitment period of 7 years, 806 patients were randomised, making ASTRAL almost 8 times larger than the largest of the previous RCTs. In all, 57 centres entered patients into ASTRAL, 53 of these were from the UK and 4 from Australasia. The initial results of ASTRAL have now been released, and the major findings are summarised below.

**ASTRAL: Key Findings**

**Renal Function**
As shown in the plot of serum creatinine (fig. 1) there was a minor deterioration in renal function over time in both treatment arms, but no difference in this change between the arms. The difference in reciprocal creatinine plot over time was the stated primary endpoint for the trial, but this too showed no significant difference between the 2 arms.

**Blood Pressure**
There was a progressive and very similar fall in blood pressure in both treatment arms (fig. 2a and b) throughout the follow-up. This amounted to about 8 mm Hg in systolic and 4 mm Hg in diastolic pressure at 36 months follow-up.

**Renal Events**
Significant renal events were analysed by the composite endpoint of time to any one of ARF, start of dialysis for ESRD, renal transplantation, nephrectomy or death due to ESRD. To date, 22% of patients in each treatment arm have had a renal event (p = 0.97); the rate of progression to dialysis-requiring ESRD has been approximately 2% per year in each treatment arm (36 patients who had been randomised to revascularization and 40 to medical therapy).

**Vascular Events**
Significant vascular endpoints included myocardial infarction, stroke, vascular death, hospitalization for angina or cardiac failure, coronary artery or peripheral vascular procedures. These have occurred in about 50% of all patients, with no difference between the treatment arms (p = 0.96).

**Mortality**
This has been almost identical in the 2 arms (103 patients in the revascularization arm and 106 in those allocated to medical therapy); as shown in the Kaplan-Meier plot in figure 3, the mortality rate has been approximately 8% per year.
Complications of Revascularization

As a result of the procedure, 6.8% of revascularized patients suffered significant complications; these included renal arterial perforation, thrombosis and embolisation (3 patients for each), serious AKI (5 patients) and groin haematoma/haemorrhage necessitating admission (n = 3). Another 20% of patients experienced less serious complications (mainly groin haematoma and short-lived renal dysfunction).

Implications of the Initial ASTRAL Trial Results

The ASTRAL trial has shown that in a large group of patients with significant anatomical atherosclerotic RAS, endovascular revascularization in addition to standard medical therapy does not improve renal functional outcome and blood pressure control, and does not reduce renal or cardiovascular events or mortality, when compared to treatment with medical therapy alone. These findings also have to be considered in the light of a significant number of revascularized patients suffering a serious complication from the procedure, which was also emphasised in the STAR study.

These findings coupled with other current evidence help guide the approach to managing patients with ARVD:

(1) In patients with clinically asymptomatic ARVD (e.g. those who are found to have the condition when referred with stable CKD and/or moderate to severe hypertension), there is no worthwhile clinical benefit associated with renal revascularization.

(2) Our current medical therapy regime for these high-risk atherosclerotic patients appears to be quite effective. In ASTRAL, the annual mortality was around 8% for all patients; in the US Medicare study involving patients aged >67 years followed from 2000–2001, the annual mortality was 16.3% for patients with ARVD and 6.4% for those without the condition. About 85% of ASTRAL patients were receiving a statin at 1 year follow-up, and 80% were receiving anti-platelet therapy.

(3) An argument can be made to stop screening patients for suspected ARVD when they are being assessed for asymptomatic CKD and/or hypertension, as revascularization would not be recommended in these patients. However, it would be important that optimal medical therapy is administered in this situation – if the patients have evidence of extra-renal atherosclerotic disease, including asymptomatic arterial bruits, then they should receive this treatment. This recommendation also applies to the practice of ‘drive-by angiography’ which often culminates in ‘drive-by stenting’ typically during coronary angiographic investigative sessions [35]. Although no firm evidence exists, it is likely that many incidental and non-functional RAS lesions are being detected and inappropriately revascularized in this way.
Current Indications for Revascularization in ARVD

Should patients with atherosclerotic RAS ever be subjected to revascularization therapy? ASTRAL never was going to be able to answer all of the questions regarding the value of revascularization in patients presenting with the following 5 specific clinical scenarios:

(1) Dialysis-requiring AKI: no trial data is available; anecdotal reports [14] show that patients can have major recovery of renal function with endovascular intervention, and there would appear to be more benefits than risks associated with revascularization.

(2) Flash pulmonary oedema: the same applies for patients presenting with severe RAS and sudden-onset pulmonary oedema that is not due to coronary artery disease; most clinicians would still recommend revascularization.

Fig. 2. a Systolic blood pressure (mm Hg) over time. b Diastolic blood pressure (mm Hg) over time [adapted from 34, with permission from the New England Journal of Medicine].
ARVD – What Have We Learned from ASTRAL?

(3) Rapidly deteriorating renal function: this was examined in a pre-specified subgroup analysis within ASTRAL, but patient numbers were <50 in each group and although serum creatinine fell at 1 year in the revascularized patients, confidence intervals were wide and the result was non-significant. The CORAL trial [36], a study of 1080 ARVD patients again with 1:1 randomization to revascularization:medical therapy, but with anatomical RAS more stringently assessed by an angiographic core laboratory, may be able to address this issue, otherwise, a future meta-analysis of such patients within ASTRAL, CORAL and STAR may be more informative.

(4) Very severe and resistant hypertension: no trial data exists. Post hoc analysis of ASTRAL data, and results from CORAL, may eventually shed light on the benefits of revascularization. Until then, some clinicians will feel obliged to attempt revascularization when patients have accelerated hypertension with severe RAS, or multidrug-resistant hypertension (e.g. >5 medications).

(5) Patients with significant anatomical RAS whose renal function deteriorates with the use of agents blocking the renin-angiotensin system: again no trial data is available to suggest that such patients have improved survival if revascularization is performed to facilitate improved ‘renal tolerance’ of these agents.

**Conclusion**

Optimal management of patients with ARVD requires an understanding of the disease processes at work. The degree of RAS is often not indicative of disease severity or severity of renal dysfunction [37], and early intra-renal damage by atherosclerosis, cholesterol formation, hypertension and cytokine release probably occur before the RAS is regarded as significant enough to warrant treatment. For example, experimentally induced hypercholesterolemia, a marker and risk factor for atherosclerosis, induces intra-renal inflammation, glomerulosclerosis, renal oxidative stress and fibrosis even in the absence of overt atherosclerotic plaques [38]. Similarly, hypertension, independently of RAS, has been shown to strongly correlate with a risk for renal atrophy in ARVD [39]. Thus, the cornerstone of ARVD management should in-
clude lifestyle modification (e.g. smoking cessation) and optimum medical care that includes cardiovascular disease management and blood pressure reduction.

Although ASTRAL has significantly increased the evidence base regarding the management of patients with ARVD, many questions still remain including the value of revascularization in the specific clinical scenarios previously described. Additional information will be provided in the future with analysis of longer term follow-up of the ASTRAL patients, and also when the results of the CORAL study (approximately 2011) are available. Whether renal revascularization can improve cardiac function and structure in patients with ARVD is also being investigated in 2 cardiac substudies of ASTRAL [40].

References


Chrysochou and Kalra update the reader on the result of the ASTRAL trial of endovascular revascularization compared to medical therapy in ARVD. They conclude that revascularization with or without stenting is of little value in long-term blood pressure control or in affecting the course of CKD. This minireview is supported by the recent publication of the STAR study group from The Netherlands drawing a similar conclusion [1]. This is not too surprising, as ARVD is not a disease confined to the renal arteries as is the case in fibromuscular dysplasia; it is a disease of older age, invariably associated with extensive intra-renal vascular and glomerular ischemic pathology. Therefore, one would not expect that the stretching of stenosed renal arteries would improve blood flow through stenosed intra-renal arteries and arterioles or improve the perfusion of ischamically sclerosed glomeruli. The authors conclude that there remain some clinical situations when percutaneous transluminal angioplasty of renal arteries may be indicated. Many nephrologists will need to be convinced by some evidence before supporting some of these recommendations. In the meanwhile, this editor would caution against investigators examining underpowered subgroups within trials as this is often misleading and can provide false-positive results. Nephrology is littered with negative clinical trials where investigators never fully accepted the evidence-based verdict; they continue to look for positive results in post hoc and underpowered subgroup analyses, but hopefully this will not occur with ASTRAL. After all, as ASTRAL clearly demonstrates, a negative result is as valuable to our practice as a positive one. The future of ARVD management will depend on developing better methods for estimating the role of large vessel occlusive disease regarding tissue oxygenation, injury and fibrosis [2].

References
